BioNTX has announced the appointment of Gina Ford, DPh., MBA, as its new chief executive officer. This decision was made by the organisation’s board of directors.
In her role as CEO, Ford is set to lead BioNTX’s strategic vision and operational priorities. Her focus will be on driving disciplined growth and ensuring that the organisation delivers meaningful and measurable value to its members. Ford aims to enhance industry alignment, elevate the national visibility of the region, and create a clear roadmap to accelerate innovation, attract investment, and improve long-term competitiveness within the life sciences sector across North Texas.
Ford expressed her enthusiasm for the position, stating, “It is a privilege to step into the role of CEO and to work with the exceptional leaders, innovators, and partners who make North Texas a dynamic hub for bioscience. BioNTX has built a powerful platform for connection and advancement, and I am committed to amplifying that impact as we enter this next stage of growth.” She further added, “I look forward to deepening strategic partnerships, broadening opportunities for innovation, and supporting the breakthroughs that will shape the region’s future.”
The selection of Ford followed a rigorous six-month review process involving multiple candidates, led by a skilled executive recruiter and a committee from the BioNTX board. Kathleen Otto Rosenblum, former CEO of BioNTX, noted, “The search process was comprehensive, ensuring we selected a leader with the vision and experience to guide BioNTX forward. Gina distinguished herself with her strong, future-focused approach to advancing bioscience and healthcare innovation in North Texas. I am confident that under her leadership, BioNTX is well-positioned for the future.”
Ford brings over two decades of leadership experience across the life sciences, biotechnology, and pharmaceutical sectors. Her previous role as CEO of Women In Bio, Inc. saw her lead significant growth in fundraising and engagement across both national and local networks, while also enhancing programmes that support women in life science careers.
With a Doctor of Pharmacy degree and an MBA, Ford possesses extensive experience that spans the bioscience life cycle, from startup and capital formation to commercialization and growth. Her long-standing commitment to improving patient outcomes aligns well with BioNTX’s mission to advance innovation that enhances lives by prioritising the patient.
Ford’s appointment is part of a leadership transition following Otto’s retirement from BioNTX after a distinguished career, which was dedicated to advancing biotech innovation in North Texas. To facilitate this transition, Otto will continue to be involved, serving as an advisor to support both Ford and the organisation.
Jason Weitjes, chair of the BioNTX board, commented, “Gina brings an exceptional depth of industry experience and an inspiring track record of growth, partnership-building, and strategic vision. We are confident that Gina’s strategic acumen, industry relationships, and operational experience will build on BioNTX’s strong foundation and support continued growth across our region. We are grateful for Kathleen’s service and pleased that she will remain engaged with BioNTX as an advisor and member of our board.”
For those interested in keeping up with developments in the North Texas business and innovation landscape, subscriptions to Dallas Innovates are available, providing curated news from Tuesday to Thursday.